Oxybugamma (Oxybutynin Hydrochloride)

Oxybutynin hydrochloride, the active ingredient in Oxybugamma, is a antispasmodic (muscarinic antagonist) presented as a 5 mg tablet for oral use. It treats symptoms of overactive bladder such as urgency, frequency, and urge incontinence in adults. GNH USA supplies Oxybugamma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxybugamma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxybugamma is an antispasmodic that acts on the urinary bladder smooth muscle to reduce involuntary contractions.

- Overactive bladder: helps reduce urinary urgency and frequency. - Urge urinary incontinence: decreases episodes of accidental leakage. - Detrusor overactivity associated with neurological conditions: improves bladder storage capacity.

Side effects reported with oxybutynin therapy vary in frequency and severity.

Common Side Effects: - Dry mouth - Constipation - Blurred vision - Drowsiness - Nausea - Headache

Serious or Rare Side Effects: - Urinary retention - Severe constipation leading to bowel obstruction - Tachycardia or arrhythmias - Allergic reactions such as rash, pruritus, or angio‑angio - Acute glaucoma - Hepatic enzyme elevation.

When prescribing Oxybugamma, clinicians should consider several safety aspects.

- Assess patient history: review any history of glaucoma or urinary retention. - Monitor renal function: dose adjustment may be needed in renal impairment. - Evaluate hepatic function: use with caution in patients with liver disease. - Avoid use in patients with known contra‑ind contra‑indications : the risk of serious effects . - Store at room temperature: keep in the original pack and protect from moisture.

Oxybugella ​  

---

---  

  """  " "  "  " ""  "" """ "" "  "  " "